Literature DB >> 3435694

Pharmacokinetics and pharmacodynamics of two formulations of verapamil.

K K Hla1, J A Henry, A N Latham.   

Abstract

The pharmacokinetics and pharmacodynamics of sustained release verapamil were compared with the conventional formulation in 10 healthy adult volunteers after single and multiple dosing. The mean time of maximum plasma concentrations of verapamil were significantly prolonged and the absorption rate constants significantly reduced after sustained release verapamil on both day 1 and day 10. On day 10 there was no significant difference between formulations in the relative bioavailability of verapamil. However, the area under the plasma concentration-time curve and maximum concentration (Cmax) for both formulations increased significantly with repeat dosing. On day 10, the difference in Cmax between formulations was significant. The day 10 mean peak/trough plasma verapamil concentration ratio was significantly less following the sustained release dose form. The mean PR interval was significantly prolonged by both formulations on day 1 and day 10. There were no differences between formulations other than a significantly longer PR interval following the conventional formulation 2 h after dosing on day 10.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3435694      PMCID: PMC1386339          DOI: 10.1111/j.1365-2125.1987.tb03226.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  16 in total

1.  Effect of a high protein meal on the bioavailability of verapamil.

Authors:  B G Woodcock; N Kraemer; N Rietbrock
Journal:  Br J Clin Pharmacol       Date:  1986-03       Impact factor: 4.335

2.  Chronopharmacokinetic study of a prolonged release form of indomethacin.

Authors:  P Guissou; G Cuisinaud; G Llorca; E Lejeune; J Sassard
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

3.  Prolongation of verapamil elimination kinetics during chronic oral administration.

Authors:  J B Schwartz; D L Keefe; E Kirsten; R E Kates; D C Harrison
Journal:  Am Heart J       Date:  1982-08       Impact factor: 4.749

4.  Rapid high-performance liquid chromatographic method for the measurement of verapamil and norverapamil in blood plasma or serum.

Authors:  S C Cole; R J Flanagan; A Johnston; D W Holt
Journal:  J Chromatogr       Date:  1981-11-20

5.  Direct determination of hepatic extraction of verapamil in cardiac patients.

Authors:  B G Woodcock; W Schulz; G Kober; N Rietbrock
Journal:  Clin Pharmacol Ther       Date:  1981-07       Impact factor: 6.875

6.  Physiological disposition of verapamil in man.

Authors:  M Schomerus; B Spiegelhalder; B Stieren; M Eichelbaum
Journal:  Cardiovasc Res       Date:  1976-09       Impact factor: 10.787

7.  The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses.

Authors:  R G McAllister; E B Kirsten
Journal:  Clin Pharmacol Ther       Date:  1982-04       Impact factor: 6.875

8.  Reduced verapamil clearance during long-term oral administration.

Authors:  D G Shand; S C Hammill; L Aanonsen; E L Pritchett
Journal:  Clin Pharmacol Ther       Date:  1981-11       Impact factor: 6.875

9.  Verapamil kinetics in normal subjects and patients with coronary artery spasm.

Authors:  S B Freedman; D R Richmond; J J Ashley; D T Kelly
Journal:  Clin Pharmacol Ther       Date:  1981-11       Impact factor: 6.875

10.  Plasma concentration--response relationship of verapamil in the treatment of angina pectoris.

Authors:  P Anderson; U Bondesson; C Sylvén; H Aström
Journal:  J Cardiovasc Pharmacol       Date:  1982 Jul-Aug       Impact factor: 3.105

View more
  5 in total

Review 1.  Clinical pharmacokinetics of calcium antagonists. An update.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

2.  Study on antihypertensive efficacy of slow-release verapamil: pharmacokinetic and noninvasive hemodynamic profile.

Authors:  V Vulpis; T M Seccia; S Ricci; P Nazzaro; A Pirrelli
Journal:  Cardiovasc Drugs Ther       Date:  1993-12       Impact factor: 3.727

Review 3.  Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

4.  Effects of prototypic calcium channel blockers in methadone-maintained humans responding under a naloxone discrimination procedure.

Authors:  Alison Oliveto; Michael Mancino; Nichole Sanders; Christopher Cargile; J Benjamin Guise; Warren Bickel; W Brooks Gentry
Journal:  Eur J Pharmacol       Date:  2013-03-21       Impact factor: 4.432

5.  Pharmacokinetics of the Novel, Selective, Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in Healthy Volunteers: Results from an Absolute Bioavailability Study and Drug-Drug Interaction Studies In Vitro and In Vivo.

Authors:  Roland Heinig; Michael Gerisch; Anna Engelen; Johannes Nagelschmitz; Stephanie Loewen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-12       Impact factor: 2.441

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.